Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Completed Phase 1 Interventional

BMS-247550 in Treating Patients With Advanced Cancers

NCT00006221
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 2 Interventional Results available

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

NCT00600821
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Adenocarcinoma
Interventions
Bevacizumab, Carboplatin, Paclitaxel, AG-013736 (axitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Baton Rouge, Louisiana • Pittsfield, Massachusetts • Columbus, Mississippi + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 31, 2026, 3:36 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Cannabis' Impact on Alcohol Consumption

NCT05389930
View directory record Official record
Conditions
Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
Interventions
THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol, Alcohol placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 50 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Building an Evidence Base for Weight Loss Strategies Among Those With Chronic SCI-The GLB-SCI+

NCT03874988
View directory record Official record
Conditions
Spinal Cord Injuries, Obesity, Weight Loss, Diet Modification
Interventions
Portion-Controlled Meals, Enhanced Self-Monitoring, GLB-SCI+
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Early Phase 1 Interventional

Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin

NCT01866462
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
NM504
Other
Lead sponsor
NuMe Health
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

NCT02642159
View directory record Official record
Conditions
Dyslipidemia
Interventions
Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intergenerational Strengths-Based Program for American Indian Girls as They Transition to Adulthood

NCT03900312
View directory record Official record
Conditions
Sexual Activity, Sex, Alcohol Use, Pregnancy, Drug Use
Interventions
Asdzaan Be'eena' Program
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
8 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chinle, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
View directory record Official record
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 31, 2026, 3:36 AM EDT
Terminated Phase 2 Interventional Results available

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

NCT00415857
View directory record Official record
Conditions
Leukemia
Interventions
Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib, GM-CSF
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 4 Interventional Results available

Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine

NCT00394095
View directory record Official record
Conditions
Bipolar Disorder, Weight Gain
Interventions
Topiramate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 3 Interventional

Study of Lumateperone in the Treatment of Patients With Bipolar Mania

NCT06462612
View directory record Official record
Conditions
Bipolar Disorder, Manic
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
22
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

NCT05798481
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

NCT00019019
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 31, 2026, 3:36 AM EDT
Recruiting Phase 3 Interventional

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

NCT04566328
View directory record Official record
Conditions
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
640
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 3:36 AM EDT
Withdrawn Phase 4 Interventional

Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide

NCT01947699
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Glyburide, Continuous glucose monitor
Drug · Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Propranolol for Protracted Labor

NCT04741698
View directory record Official record
Conditions
Labour;Obstructed, Labor Dystocia
Interventions
Propranolol
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 31, 2026, 3:36 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects

NCT06922084
View directory record Official record
Conditions
Cataract
Interventions
Clareon PanOptix, Clareon PanOptix PRO, Mix-and-Match PanOptix/Vivity
Device · Drug
Lead sponsor
Berkeley Eye Center
Other
Eligibility
40 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Plymouth Meeting, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Not applicable Interventional

Evaluating a Web Delivered Behavioral Parent Training Intervention for Rural Parents of Children With Autism Spectrum Disorder

NCT05554198
View directory record Official record
Conditions
Autism Spectrum Disorder, Parenting, Parenting Intervention
Interventions
Attend Behavior Parent Training
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
2 Years to 11 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 31, 2026, 3:36 AM EDT
Not yet recruiting Phase 4 Interventional

Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty

NCT07097493
View directory record Official record
Conditions
Knee Arthroplasty, Total
Interventions
Liposomal Bupivacaine, Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Phase 2 Interventional

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

NCT00357084
View directory record Official record
Conditions
Cancer
Interventions
methotrexate, methylprednisolone, prednisone
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Not applicable Interventional

Improving Tolerability of Bowel Preparation Laxative for Colonoscopy

NCT02062112
View directory record Official record
Conditions
Colonoscopy, Bowel Preparation
Interventions
Pattern of flavoring of bowel laxative
Other
Lead sponsor
Howard University
Other
Eligibility
18 Years to 100 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 31, 2026, 3:36 AM EDT
Completed Not applicable Interventional

Randomized Double-Blind Controlled Clinical Trial

NCT04320628
View directory record Official record
Conditions
Chronic Wounds, Acute Wounds
Interventions
AnaSept®, NSS
Device · Other
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 31, 2026, 3:36 AM EDT
Terminated Phase 2 Interventional Results available

Urea for Chronic Hyponatremia

NCT04588207
View directory record Official record
Conditions
Hyponatremia, Inappropriate ADH Syndrome
Interventions
Urea
Drug
Lead sponsor
Helbert Rondon Berrios, MD, MS
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 31, 2026, 3:36 AM EDT